A Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Study of the Safety, Tolerability and Pharmacokinetics of CMX157 in Healthy Adult Volunteers.

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Study of the Safety, Tolerability and Pharmacokinetics of CMX157 in Healthy Adult Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Dec 2015

At a glance

  • Drugs Tenofovir exalidex (Primary) ; Tenofovir disoproxil fumarate
  • Indications Hepatitis B; HIV infections; Lipid metabolism disorders
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Dec 2015 According to a ContraVir Pharmaceuticals media release, data from this study will be presented at the HEP DART 2015.
    • 13 Dec 2010 Results presented at the 2101 Frontiers in Drug Development for Antiretroviral Therapies conference, according to a Chimerix media release
    • 07 Nov 2010 Status changed from active, no longer recruiting to completed, according to a Chimerix media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top